Maternally inherited hypercholesterolemia does not modify the cardiovascular phenotype in familial hypercholesterolemia.

Victoria Marco-Benedí, Martín Laclaustra, Ana M Bea, Manuel Suarez-Tembra, Núria Plana, Xavier Pinto, Angel Brea, Rosa M Sanchez-Hernandez, Fernando Civeira

Journal: Atherosclerosis 2021;320():47-52

PMID: 33529866

Abstract

BACKGROUND AND AIMS

Familial hypercholesterolemia (FH) is a codominant autosomal disease characterized by a high risk of cardiovascular disease when not in lipid-lowering treatment. However, there is a large variability in the clinical presentation in heterozygous subjects (HeFH). Maternal hypercholesterolemia has been proposed as a cardiometabolic risk factor later in life. Whether this phenotype variability depends on the mother or father origin of hypercholesterolemia is unknown. The objective of this study was to analyze potential differences in anthropometry, superficial lipid deposits, comorbidities, and lipid concentrations depending on the parental origin of hypercholesterolemia within a large group of HeFH.

METHODS

This is a cross-sectional observational, multicenter, nation-wide study in Spain. We recruited adults with HeFH to study clinical differences according to the parental origin. Data on HeFH patients were obtained from the Dyslipidemia Registry of the Spanish Atherosclerosis Society.

RESULTS

HeFH patients were grouped in 1231 HeFH-mother-offspring aged 45.7 (16.3) years and 1174 HeFH-father-offspring aged 44.8 (16.7) years. We did not find any difference in lipid parameters (total cholesterol, triglycerides, LDLc, HDLc, and Lp(a)), nor in the comorbidities studied (cardiovascular disease prevalence, age of onset of cardiovascular disease, obesity, diabetes, and hypertension) between groups. Lipid-lowering treatment did not differ between groups. The prevalence of comorbidities did not show differences when they were studied by age groups.

CONCLUSIONS

Our research with a large group of subjects with HeFH shows that a potential maternal effect is not relevant in FH. However, due to the size of our sample, potential differences between genders cannot be completely ruled out. This implies that severe maternal hypercholesterolemia during pregnancy is not associated with additional risk in the FH affected offspring.

Copyright © 2021 Elsevier B.V. All rights reserved.

Address: Hospital Universitario Miguel Servet, IIS Aragón, Cibercv, Spain.; Hospital Universitario Miguel Servet, IIS Aragón, Cibercv, Spain; Fundación Agencia Aragonesa para La Investigación y El Desarrollo (ARAID), Zaragoza, Spain. Electronic address: [email protected].; Servicio de Medicina Interna, Unidad de Lípidos y Riesgo Cardiovascular, Hospital San Rafael, A Coruña, Spain.; Unitat de Medicina Vascular I Metabolisme (UVASMET) Hospital Universitari Sant Joan, IISPV, CIBERDEM, Universitat Rovira I Virgili, Reus, Tarragona, Spain.; Unidad de Lípidos. Servicio de Medicina Interna. Hospital Universitario de Bellvitge-Idibell. Universidad de Barcelona, CiberObn, Spain.; Unidad de Lípidos. Servicio de Medicina Interna. Hospital San Pedro, Logroño, Spain.; Sección de Endocrinología y Nutrición, Complejo Hospitalario Universitario Insular Materno Infantil de Gran Canaria, Instituto Universitario de Investigaciones Biomédicas y Sanitarias (IUIBS) de La Universidad de Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Spain.; Hospital Universitario Miguel Servet, IIS Aragón, Cibercv, Spain; Universidad de Zaragoza, Zaragoza, Spain. Electronic address: [email protected].
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.